^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SU6656

i
Other names: SU6656, SU-6656, SU 6656
Company:
Hokkaido University, Pfizer
Drug class:
Aurora kinase inhibitor, SRC-family kinase (SFK) inhibitor
over1year
Kaempferol suppresses glioma progression and synergistically enhances the antitumor activity of gefitinib by inhibiting the EGFR/SRC/STAT3 signaling pathway. (PubMed, Drug Dev Res)
Similarly, Kae further enhanced the inhibition of p-SRC caused by SU6656. Kae played a potential role and synergistic antiglioma effects with Gef by inhibiting the phosphorylation of EGFR/SRC dual targets. Kae is expected to be a candidate drug or chemosensitizer in glioma therapy.
Journal
|
SRC (SRC Proto-Oncogene)
|
gefitinib • SU6656
over2years
Fyn and argonaute 2 participate in maternal-mRNA degradation during mouse oocyte maturation. (PubMed, Cell Cycle)
Our aim was to examine the role of Fyn and AGO2 in degradation of maternal-mRNAs during oocyte maturation by either suppressing their activity with SU6656 - an SFKs inhibitor; or by microinjecting DN-Fyn RNA for suppression of Fyn and BCl-137 for suppression of AGO2...Inhibition of AGO2 prevented the degreadation of at least five maternal-mRNAs, whereas inhibition of Fyn/SFK prevented degradation of at least five Fyn maternal-mRNAs and two SFKs maternal-mRNAs; pointing at their role in promoting the physiological degradation which occurs during in-vivo oocyte maturation. Our findings imply the involvement of Fyn/SFKs in stabilization of maternal-mRNA at the GV stage and the involvement of Fyn, SFKs and AGO2 in degradation of maternal mRNAs during oocyte maturation.
Preclinical • Journal
|
AGO2 (Argonaute RISC Catalytic Component 2)
|
SU6656